Formoterol, a new long acting beta 2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma

Wallin, A; Melander, B; Rosenhall, L; Sandström, T; Wåhlander, L
April 1990
Thorax;Apr1990, Vol. 45 Issue 4, p259
Academic Journal
No abstract available.


Related Articles

  • Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials. Haney, Sarah; Hancox, Robert J. // Respiratory Research;2007, Vol. 8, p19 

    Background: Asthmatics treated with long-acting beta-agonists have a reduced bronchodilator response to moderate doses of inhaled short acting beta-agonists during acute bronchoconstriction. It is not known if the response to higher doses of nebulised beta-agonists or other bronchodilators is...

  • Formoterol: An Update of its Pharmacological Properties and Therapeutic Efficacy in the Management of Asthma. Bartow, R.A.; Brogden, R.N. // Drugs;Feb1998, Vol. 55 Issue 2, p303 

    Formoterol, a selective β2-adrenoceptor agonist, produces effective dose-proportional bronchodilation, which persists for up to 12 hours, in patients with reversible obstructive respiratory disease. Bronchodilation is significant within minutes of inhalation, maximal within 2 hours, and at...

  • Budesonide/formoterol maintenance and reliever therapy in moderate-to-severe asthma: Effects on eosinophilic airway inflammation. Takeyama, Kiyoshi; Kondo, Mitsuko; Tagaya, Etsuko; Kirishi, Saori; Ishii, Masanobu; Ochiai, Katsunori; Isono, Kazuo; Tamaoki, Jun // Allergy & Asthma Proceedings;Mar/Apr2014, Vol. 35 Issue 2, p141 

    Although the budesonide and formoterol in a single inhaler for maintenance and reliever therapy has been evaluated in recent studies, the effects on eosinophilic airway inflammation remain uncertain. The purpose of this study was to compare the efficacy, including anti-inflammatory effects, of...

  • Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial. Haney, Sarah; Hancox, Robert J. // Respiratory Research;2005, Vol. 6, p107 

    Background: Regular use of beta-agonists leads to tolerance to their bronchodilator effects. This can be demonstrated by measuring the response to beta-agonist following bronchoconstriction using methacholine. However most studies have demonstrated tolerance after a period of betaagonist...

  • Long-Acting Beta-Agonists and their Association with Inhaled Corticosteroids in COPD. Fuso, L.; Mores, N.; Valente, S.; Malerba, M.; Montuschi, P. // Current Medicinal Chemistry;Apr2013, Vol. 20 Issue 10-13, p1477 

    Inhaled bronchodilators, including beta2-agonists and antimuscaric receptor antagonists, are the mainstay of pharmacotherapy in chronic obstructive pulmonary disease (COPD). The short-acting beta2-agonists, including salbutamol, and fenoterol, have a rapid onset of action, a bronchodilating...

  • Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma: Commentary. Rees, P. John // Evidence Based Medicine;Aug2005, Vol. 10 Issue 4, p116 

    Focuses on the control of asthma by inhaled long acting beta agonists and corticosteroids. Effectiveness of the combination of fluticasone/salmeterol and budesonide/formoterol; Dose response of corticosteroids and formoterol; Onset of bronchodilation.

  • Independent Nurse: Beta-agonists may increase asthma risk.  // GP: General Practitioner;12/9/2005, p82 

    This article focuses on a study conducted by Swiss researchers, according to which short-acting beta-agonist bronchodilators can increase the risk of severe asthma attacks. The team used mathematical modelling to try and predict when an asthma attack might occur in an individual. They recruited...

  • Fluticasone Propionate/Formoterol Fumarate: A Review of Its Use in Persistent Asthma. Mckeage, Kate // Drugs;2013, Vol. 73 Issue 2, p195 

    The corticosteroid fluticasone propionate (fluticasone) and the long-acting β-adrenoceptor agonist formoterol fumarate (formoterol) have been combined in a single, pressurized, metered-dose, aerosol inhaler for the maintenance treatment of patients aged ≥12 years with persistent asthma....

  • New safety information on long-acting beta-2 agonists.  // WHO Drug Information;2005, Vol. 19 Issue 4, p289 

    The article provides information pertaining to the increased risk of asthma-related deaths associated with long-acting beta-2 agonists. Such medications involved in the prevention of the asthma include salmeterol, formoterol, and two combination products containing salmeterol or formoterol in...

  • Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma. Pauwels, Romain A.; Löfdahl, Claes-Göran; Postma, Dirkje S.; Tattersfield, Anne E.; O'Byrne, Paul; Barnes, Peter J.; Ullman, Anders // New England Journal of Medicine;11/13/97, Vol. 337 Issue 20, p1405 

    Background: The role of long-acting, inhaled β2-agonists in treating asthma is uncertain. In a double-blind study, we evaluated the effects of adding inhaled formoterol to both lower and higher doses of the inhaled glucocorticoid budesonide. Methods: After a four-week run-in period of...


Read the Article


Sign out of this library

Other Topics